Dr. Smith Discusses Double-Hit and Triple-Hit Lymphoma

Sonali M. Smith, MD
Published: Monday, Jul 30, 2018



Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses double-hit and triple-hit lymphoma.

The classification for lymphoma has changed and evolved over the years, Smith says. Certain lymphomas have very aggressive morphologic features, as well as biologic features, that can change the prognosis of a patient if identified. The discovery of these features signaled the need for a change in the classification of lymphoma, Smith says.

The MYC rearrangement, which is classically seen in Burkitt lymphoma, is now known to occur in 10% to 15% of patients with unselected diffuse large B-cell lymphoma. The WHO created a new category after it was discovered that these patients have a poor outcome after R-CHOP therapy. This category is called double-hit or triple-hit high-grade B-cell lymphoma based on the presence of an aggressive B-cell morphology plus a MYC rearrangement, and a BCL2 or BCL6 rearrangement.


Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses double-hit and triple-hit lymphoma.

The classification for lymphoma has changed and evolved over the years, Smith says. Certain lymphomas have very aggressive morphologic features, as well as biologic features, that can change the prognosis of a patient if identified. The discovery of these features signaled the need for a change in the classification of lymphoma, Smith says.

The MYC rearrangement, which is classically seen in Burkitt lymphoma, is now known to occur in 10% to 15% of patients with unselected diffuse large B-cell lymphoma. The WHO created a new category after it was discovered that these patients have a poor outcome after R-CHOP therapy. This category is called double-hit or triple-hit high-grade B-cell lymphoma based on the presence of an aggressive B-cell morphology plus a MYC rearrangement, and a BCL2 or BCL6 rearrangement.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x